{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T07:45:53Z","timestamp":1777535153213,"version":"3.51.4"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2100,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1002\/hep.23204","type":"journal-article","created":{"date-parts":[[2009,8,5]],"date-time":"2009-08-05T17:58:14Z","timestamp":1249495094000},"page":"1719-1726","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":21,"title":["Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders\u2020\u2021"],"prefix":"10.1097","volume":"50","author":[{"given":"Vinod K.","family":"Rustgi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William M.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Lawitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart C.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nezam","family":"Afdhal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred","family":"Poordad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert L.","family":"Bonkovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leif","family":"Bengtsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gurudatt","family":"Chandorkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Harding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay","family":"McNair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Molly","family":"Aalyson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Alam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Kauffman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahin","family":"Gharakhanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John G.","family":"McHutchison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-8-20241201","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa\u20102a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"R2-8-20241201","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon\u2010alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"key":"R3-8-20241201","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa\u20102b plus ribavirin compared with interferon alfa\u20102b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"R4-8-20241201","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11894-006-0063-z","article-title":"Chronic hepatitis C: treatment of pegylated interferon\/ribavirin nonresponders","volume":"8","author":"Shiffman","year":"2006","journal-title":"Curr Gastroenterol Rep"},{"key":"R5-8-20241201","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/jac\/dki405","article-title":"Treating HCV with ribavirin analogues and ribavirin\u2010like molecules","volume":"57","author":"Gish","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"R6-8-20241201","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1128\/AAC.47.1.426-431.2003","article-title":"Activation and deactivation of a broad\u2010spectrum antiviral drug by a single enzyme: adenosine deaminase catalyzes two consecutive deamination reactions","volume":"47","author":"Wu","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"R7-8-20241201","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1128\/AAC.44.4.859-866.2000","article-title":"Broad\u2010spectrum antiviral activity of the IMP dehydrogenase inhibitor VX\u2010497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon","volume":"44","author":"Markland","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"R8-8-20241201","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0042-6822(03)00152-1","article-title":"The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA","volume":"310","author":"Zhou","year":"2003","journal-title":"Virology"},{"key":"R9-8-20241201","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1177\/135965350501000503","article-title":"A randomized, double\u2010blind, placebo\u2010controlled dose\u2010escalation trial of merimepodib (VX\u2010497) and interferon\u2010alpha in previously untreated patients with chronic hepatitis C","volume":"10","author":"McHutchison","year":"2005","journal-title":"Antivir Ther"},{"key":"R10-8-20241201","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jhep.2007.03.028","article-title":"Phase 2 study of the combination of merimepodib with peginterferon\u2010alpha2b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C","volume":"47","author":"Marcellin","year":"2007","journal-title":"J Hepatol"},{"key":"R11-8-20241201","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1128\/JCM.42.8.3739-3746.2004","article-title":"Performance characteristics of a quantitative TaqMan hepatitis C virus RNA analyte\u2010specific reagent","volume":"42","author":"Barbeau","year":"2004","journal-title":"J Clin Microbiol"},{"key":"R12-8-20241201","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/biomet\/75.4.800","article-title":"A sharper Bonferroni procedure for multiple tests of significance","volume":"75","author":"Hochberg","year":"2007","journal-title":"Biometrika"},{"key":"R13-8-20241201","doi-asserted-by":"crossref","first-page":"S369","DOI":"10.1016\/S0168-8278(08)60990-3","article-title":"Sustained viral response (SVR) is dependent on baseline characteristics in the retreatment of previous alfa interferon\/ribavirin (I\/R) nonresponders (NR): final results from the epic3 program","volume":"48","author":"Poynard","year":"2008","journal-title":"J Hepatol"},{"key":"R14-8-20241201","doi-asserted-by":"crossref","first-page":"S370","DOI":"10.1016\/S0168-8278(08)60993-9","article-title":"Final results of the IDEAL (individualized dosing efficacy versus flat dosing to assess optimal pegylated interferon therapy) phase IIIb study","volume":"48","author":"Sulkowski","year":"2008","journal-title":"J Hepatol"},{"key":"R17-8-20241201","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04082","article-title":"Mechanism of action of interferon and ribavirin in treatment of hepatitis C","volume":"436","author":"Feld","year":"2005","journal-title":"Nature"},{"key":"R18-8-20241201","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.intimp.2004.09.010","article-title":"Impact of mycophenolate mofetil versus azathioprine on early recurrence of hepatitis C after liver transplantation","volume":"5","author":"Kornberg","year":"2005","journal-title":"Int Immunopharmacol"},{"key":"R19-8-20241201","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1191\/0961203305LU2122OA","article-title":"Mycophenolate mofetil in patients with hepatitis C virus infection","volume":"14","author":"Ramos\u2010Casals","year":"2005","journal-title":"Lupus"},{"key":"R20-8-20241201","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.bbrc.2005.03.062","article-title":"Mizoribine inhibits hepatitis C virus RNA replication: Effect of combination with interferon\u2010alpha","volume":"330","author":"Naka","year":"2005","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.23204","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200912000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T13:26:22Z","timestamp":1733059582000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200912000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.23204","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}